系统性红斑狼疮患者的肝脏受累研究进展
Research Progress of Liver Involvement in Patients with Systemic Lupus Erythematosus
摘要: 系统性红斑狼疮(systemic lupus erythematosus, SLE)患者在病程中常伴有肝功能异常,由狼疮本病导致的肝损伤称为狼疮性肝炎(lupus hepatitis, LH)。系统性红斑狼疮患者肝脏受累的临床症状通常是轻微和非特异性的,例如:恶心、乏力、腹胀、腹痛等,肝衰竭、非肝硬化门静脉高压、肝性脑病等情况罕见。目前狼疮性肝炎的发病机制尚不明确,有文献推测补体沉积和血管炎是两种可能的机制。狼疮性肝炎尚无统一的诊断标准,需除外其他病因,必要时需通过肝穿刺活检来明确病因诊断。狼疮性肝炎被认为是SLE疾病活动的结果,且与疾病活动度相关的指标密切相关,予以激素及免疫抑制剂治疗后,肝酶水平随着疾病的控制而显著下降。本文对PubMed数据库进行全面的文献检索,对LH的发病机制、临床特点、诊断和治疗等研究进展进行讨论并作一综述。
Abstract: Patients with systemic lupus erythematosus (systemic lupus erythematosus, SLE) are often accom-panied with abnormal liver function during the course of the disease. The liver injury caused by SLE is called lupus hepatitis (lupus hepatitis, LH). The clinical symptoms of liver involvement in patients with systemic lupus erythematosus are usually mild and non-specific, such as nausea, fatigue, ab-dominal distension, abdominal pain and so on. Liver failure, non-cirrhotic portal hypertension and hepatic encephalopathy are rare. At present, the pathogenesis of lupus hepatitis is not clear, and some literatures speculate that complement deposition and vasculitis are two possible mecha-nisms. There is no unified diagnostic standard for lupus hepatitis, and other causes should be ex-cluded. If necessary, liver biopsy should be used to confirm the etiological diagnosis. Lupus hepatitis is considered to be the result of SLE disease activity, and is closely related to disease activity. After treatment with hormones and immunosuppressants, liver enzyme levels decreased significantly with the control of the disease. This paper makes a comprehensive literature search of PubMed da-tabase, and discusses and reviews the research progress on the pathogenesis, clinical features, di-agnosis and treatment of LH.
文章引用:刘茂萍, 唐琳. 系统性红斑狼疮患者的肝脏受累研究进展[J]. 临床医学进展, 2024, 14(1): 1228-1235. https://doi.org/10.12677/ACM.2024.141178

参考文献

[1] Chowdhary, V.R., Crowson, C.S., Poterucha, J.J., et al. (2008) Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients. The Journal of Rheumatology, 35, 2159-2164. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, Y., Yu, J., Oaks, Z., et al. (2015) Liver Injury Correlates with Biomarkers of Autoimmunity and Disease Activity and Represents an Organ System Involvement in Patients with Sys-temic Lupus Erythematosus. Clinical Immunology, 160, 319-327. [Google Scholar] [CrossRef] [PubMed]
[3] Afzal, W., Haghi, M., Hasni, S.A. and Newman, K.A. (2020) Lu-pus Hepatitis, More than Just Elevated Liver Enzymes. The Scandinavian Journal of Rheumatology, 49,427-433. [Google Scholar] [CrossRef] [PubMed]
[4] Takahashi, A., Abe, K., Saito, R., et al. (2013) Liver Dys-function in Patients with Systemic Lupus Erythematosus. Internal Medicine, 52, 1461-1465. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, H., Han, H., Li, J., et al. (2019) Alpha-Hydroxybutyrate Dehydrogenase as a Biomarker for Predicting Systemic Lupus Erythematosus with Liver Injury. International Im-munopharmacology, 77, Article ID: 105922. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, C.-R. and Tsai, H.-W. (2022) Autoimmune Liver Dis-eases in Systemic Rheumatic Diseases. World Journal of Gastroenterology, 28, 2527-2545. [Google Scholar] [CrossRef] [PubMed]
[7] Cai, R., Liu, M., Hu, Y., et al. (2017) Identification of Adverse Drug-Drug Interactions through Causal Association Rule Discovery from Spontaneous Adverse Event Reports. Artificial Intelligence in Medicine, 76, 7-15. [Google Scholar] [CrossRef] [PubMed]
[8] Ohira, H. (2004) High Frequency of Anti-Ribosomal P Anti-body in Patients with Systemic Lupus Erythematosus-Associated Hepatitis. Hepatology Research, 28, 137-139. [Google Scholar] [CrossRef] [PubMed]
[9] Calich, A.L., Viana, V.S.T., Cancado, E., et al. (2013) An-ti-Ribosomal P Protein: A Novel Antibody in Autoimmune Hepatitis. Liver International, 33, 909-913. [Google Scholar] [CrossRef] [PubMed]
[10] Piga, M., Vacca, A., Porru, G., et al. (2010) Liver Involvement in Systemic Lupus Erythematosus: Incidence, Clinical Course and Outcome of Lupus Hepatitis. Clinical and Experimental Rheuma-tology, 28, 504-510.
[11] Barber, M., et al. (2021) Global Epidemiology of Systemic Lupus Erythematosus. Nature Re-views. Rheumatology, 17, 515-532. [Google Scholar] [CrossRef] [PubMed]
[12] Isenberg, D.A., Rahman, A., Allen, E., et al. (2004) BILAG 2004. Development and Initial Validation of an Updated Version of the British Isles Lu-pus Assessment Group’s Disease Activity Index for Patients with Systemic Lupus Erythematosus. Rheumatology, 44, 902-906. [Google Scholar] [CrossRef] [PubMed]
[13] Manderson, A.P., Botto, M. and Walport, M.J. (2004) The Role of Complement in the Development of Systemic Lupus Erythematosus. Annual Review of Immunology, 22, 431-456. [Google Scholar] [CrossRef] [PubMed]
[14] Drenkard, C., Villa, A.R., Reyes, E., et al. (1997) Vasculitis in Systemic Lupus Erythematosus. Lupus, 6, 235-242. [Google Scholar] [CrossRef] [PubMed]
[15] Ramos-Casals, M., Nardi, N., Lagrutta, M., et al. (2006) Vas-culitis in Systemic Lupus Erythematosus: Prevalence and Clinical Characteristics in 670 Patients. Medicine, 85, 95-104. [Google Scholar] [CrossRef] [PubMed]
[16] Patel, A. and Perl, A. (2022) Redox Control of Integ-rin-Mediated Hepatic Inflammation in Systemic Autoimmunity. Antioxidants & Redox Signaling, 36, 367-388.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982133/
[17] Bessone, F. (2014) Challenge of Liver Disease in Systemic Lupus Erythematosus: Clues for Diagnosis and Hints for Pathogenesis. World Journal of Hepatology, 6, 394-409. [Google Scholar] [CrossRef] [PubMed]
[18] Arnett, F.C. and Reichlin, M. (1995) Lupus Hepatitis: An Under-Recognized Disease Feature Associated with Autoantibodies to Ribosomal P. The American Journal of Medicine, 99, 465-472. [Google Scholar] [CrossRef
[19] Willeke, P., Schlüter, B., Limani, A., et al. (2016) Liver In-volvement in ANCA-Associated Vasculitis. Clinical Rheumatology, 35, 387-394. [Google Scholar] [CrossRef] [PubMed]
[20] González-Regueiro, J.A., Cruz-Contreras, M., Merayo-Chalico, J., et al. (2020) Hepatic Manifestations in Systemic Lupus Erythematosus. Lupus, 29, 813-824. [Google Scholar] [CrossRef] [PubMed]
[21] Solela, G. and Daba, M. (2023) Budd-Chiari Syndrome as an Ini-tial Presentation of Systemic Lupus Erythematosus Associated with Antiphospholipid Syndrome: A Case Report with Review of the Literature. Open Access Rheumatology: Research and Reviews, 15, 139-143. [Google Scholar] [CrossRef
[22] Zheng, R.-H., et al. (2013) Clinical and Immunopathological Fea-tures of Patients with Lupus Hepatitis. Chinese Medical Journal, 126, 260-266. [Google Scholar] [CrossRef
[23] Fang, X., Zaman, M.H., Guo, X., et al. (2018) Role of Hepatic Deposited Immunoglobulin G in the Pathogenesis of Liver Damage in Systemic Lupus Erythematosus. Fron-tiers in Immunology, 9, Article No. 1457. [Google Scholar] [CrossRef] [PubMed]
[24] 韩晓晓, 邓国民. 狼疮血清IgG对系统性红斑狼疮多器官损害的作用机制[C]//中国免疫学会. 第十四届全国免疫学学术大会论文摘要汇编. 2021: 377.
[25] Matsumoto, T., Kobayashi, S., Shimizu, H., et al. (2000) The Liver in Collagen Diseases: Pathologic Study of 160 Cases with Particular Reference to Hepatic Arteritis, Primary Biliary Cirrhosis, Autoimmune Hepatitis and Nodular Regenerative Hyperplasia of the Liver: Liver in Collagen Diseases. Liver, 20, 366-373. [Google Scholar] [CrossRef] [PubMed]
[26] Haslock, I. (1974) Spontaneous Rupture of the Liver in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 33, 482-484. [Google Scholar] [CrossRef] [PubMed]
[27] Krauser, R.E. (1976) Spontaneous Rupture of the Spleen in Systemic Lupus Erythematosus. JAMA, 236, 1149.
[28] You, H., Peng, L., Zhao, J., et al. (2020) Clinical Characteristics of Sys-temic Lupus Erythematosus with Cirrhosis. Journal of Immunology Research, 2020, Article ID: 2156762. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, L., Yin, L., Lv, W., et al. (2023) Clinical Analysis of Patients with Systemic Lupus Erythematosus Complicated with Liver Failure. Clinical Rheumatology, 42, 1545-1553. [Google Scholar] [CrossRef] [PubMed]
[30] Efe, C., Purnak, T., Ozaslan, E., et al. (2011) Autoimmune Liver Disease in Patients with Systemic Lupus Erythematosus: A Retrospective Analysis of 147 Cases. Scandinavian Journal of Gastroenterology, 46, 732-737. [Google Scholar] [CrossRef] [PubMed]
[31] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021) [J]. 中华肝脏病杂志, 2022, 30(5): 482-492. [Google Scholar] [CrossRef
[32] Heneghan, M.A., Yeoman, A.D., Verma, S., et al. (2013) Autoimmune Hepatitis. The Lancet, 382, 1433-1444. [Google Scholar] [CrossRef
[33] Arvaniti, P., Giannoulis, G., Gabeta, S., et al. (2020) Belimumab Is a Promising Third-Line Treatment Option for Refractory Autoimmune Hepatitis. JHEP Reports, 2, Article ID: 100123. [Google Scholar] [CrossRef] [PubMed]
[34] Kolev, M., Sarbu, A.-C., Möller, B., et al. (2023) Belimumab Treatment in Autoimmune Hepatitis and Primary Biliary Cholangitis—A Case Series. Journal of Transla-tional Autoimmunity, 6, Article ID: 100189. [Google Scholar] [CrossRef] [PubMed]
[35] Kottyan, L.C., Zoller, E.E., Bene, J., et al. (2015) The IRF5-TNPO3 Association with Systemic Lupus Erythematosus Has Two Components That Other Autoimmune Disor-ders Variably Share. Human Molecular Genetics, 24, 582-596. [Google Scholar] [CrossRef] [PubMed]
[36] Ebert, E.C. and Hagspiel, K.D. (2011) Gastrointestinal and Hepatic Man-ifestations of Systemic Lupus Erythematosus. Journal of Clinical Gastroenterology, 45, 436-441. [Google Scholar] [CrossRef
[37] Li, L., Jiang, W. and Wang, J. (2007) Clinical Analysis of 275 Cases of Acute Drug-Induced Liver Disease. Frontiers of Medicine in China, 1, 58-61. [Google Scholar] [CrossRef] [PubMed]
[38] Gebreselassie, A., Aduli, F. and Howell, C.D. (2019) Rheumato-logic Diseases and the Liver. Clinics in Liver Disease, 23, 247-261. [Google Scholar] [CrossRef] [PubMed]
[39] Visser, K., Katchamart, W., Loza, E., et al. (2009) Multinational Ev-idence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders with a Focus on Rheumatoid Ar-thritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative. Annals of the Rheumatic Diseases, 68, 1086-1093. [Google Scholar] [CrossRef] [PubMed]
[40] Conway, R. and Carey, J.J. (2017) Risk of Liver Disease in Metho-trexate Treated Patients. World Journal of Hepatology, 9, 1092-1100. [Google Scholar] [CrossRef] [PubMed]
[41] Lee, Y.H., Bae, S.-C. and Song, G.G. (2013) Hepatitis B Virus Reac-tivation in HBsAg-Positive Patients with Rheumatic Diseases Undergoing Anti-Tumor Necrosis Factor Therapy or DMARDs. International Journal of Rheumatic Diseases, 16, 527-531. [Google Scholar] [CrossRef
[42] Chen, M.-H., Chen, M.-H., Liu, C.-Y., et al. (2016) Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. Journal of Infectious Diseases, 215, 566-573. [Google Scholar] [CrossRef] [PubMed]
[43] Chen, M.-H., Chen, M.-H., Chou, C.-T., et al. (2020) Low but Long-Lasting Risk of Reversal of Seroconversion in Patients with Rheumatoid Arthritis Receiving Immunosuppressive Therapy. Clinical Gastroenterology and Hepatology, 18, 2573-2581.e1. [Google Scholar] [CrossRef] [PubMed]
[44] Yeo, W., Zee, B., Zhong, S., et al. (2004) Comprehensive Analysis of Risk Factors Associating with Hepatitis B Virus (HBV) Reactivation in Cancer Patients Undergoing Cytotoxic Chem-otherapy. British Journal of Cancer, 90, 1306-1311. [Google Scholar] [CrossRef] [PubMed]
[45] Chen, M.-H., Wu, C.-S., Chen, M.-H., et al. (2021) High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythe-matosus. International Journal of Molecular Sciences, 22, Article No. 9116. [Google Scholar] [CrossRef] [PubMed]
[46] You, H., Wang, F., Li, T., et al. (2023) Guidelines for the Prevention and Treatment of Chronic Hepatitis B (Version 2022). Journal of Clinical and Translational Hepatology, 11, 1425-1442. [Google Scholar] [CrossRef
[47] Huang, D., Aghdassi, E., Su, J., et al. (2012) Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology, 39, 254-261. [Google Scholar] [CrossRef] [PubMed]
[48] Maiorino, M.I., Bellastella, G., Giugliano, D., et al. (2017) Cooling down Inflammation in Type 2 Diabetes: How Strong Is the Evidence for Cardiometabolic Benefit? Endocrine, 55, 360-365. [Google Scholar] [CrossRef] [PubMed]
[49] Qiao, X., Zhou, Z.-C., Niu, R., et al. (2019) Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism. Frontiers in Pharmacology, 10, Article No. 855. [Google Scholar] [CrossRef] [PubMed]
[50] Rempenault, C., Combe, B., Barnetche, T., et al. (2018) Metabolic and Cardiovascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases, 77, 98-103.